6533b838fe1ef96bd12a3bf1

RESEARCH PRODUCT

Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease

José Luis GorrizDavid ArroyoLuis D'marcoRoser Torra BalcellsPatricia TomásMaría Jesús PuchadesNayara PanizoJonay PantojaMarco MontomoliJosé Luis LlisterriVicente Pallares-carratalaJosé Manuel ValdivielsoUniversitat Autònoma De Barcelona

subject

MaleNephrologymedicine.medical_specialtyAutosomal dominant polycystic kidney diseaseRenal functionComorbiditylcsh:RC870-923urologic and male genital diseasesCarotid Intima-Media ThicknessAsymptomaticNephropathyAutosomal dominant polycystic kidney diseaseInternal medicineChronic kidney diseasemedicineHumansAnkle Brachial Indexcardiovascular diseasesRenal Insufficiency ChronicProteinuriabusiness.industryMiddle AgedPolycystic Kidney Autosomal DominantPrognosislcsh:Diseases of the genitourinary system. Urologymedicine.diseaseCardiovascular diseasePlaque Atheroscleroticfemale genital diseases and pregnancy complicationsNephropathyCor MalaltiesBlood pressureCardiovascular DiseasesHeart Disease Risk FactorsNephrologyDisease ProgressionInsuficiència renal crònicaFemalemedicine.symptombusinessResearch ArticleKidney disease

description

Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent hereditary renal disease. There is an increased rate of cardiovascular disease (CVD) in ADPKD. In this study, we evaluate the prevalence of cardiovascular risk factors, the achievement rates for treatment goals and cardiovascular events (CVE) in ADPKD and their relations with asymptomatic CVD in CKD from other etiologies (CKDoe) and controls. Methods: We evaluated 2445 CKD patients (2010–2012). The information collected was: clinical, anthropometric and analytical parameters, treatments and CVD evaluation (intima-media thickness (IMT), atheromatous plaque presence and ankle-brachial index (ABI)). Laboratory, vital status, CVE and hospitalizations were collected for 4 years. Results: ADPKD patients had a worse renal function and worst achievement of blood pressure, higher parathormone levels but lower proteinuria compared to CKDoe. ADPKD patients presented lower IMT values than other groups, however, an intermediate rate of pathologic ABI and atheromatous plaque was present. More than half of the patients received statins, achieving LDL-c levels < 100 only in 50 and 39.8% of them (ADPKD and CKDoe respectively). The number of CVE during the follow-up period was low. In adjusted Cox regression model, ADPDK had the lowest occurrence of CVE of all three groups (HR:0.422, 95%CI 0.221–0.808, p = 0.009). Conclusion: ADPKD patients show intermediate control rates of CVD. A better control of CVD risk seems to be related with a lower load of CVD compared to other groups, which may lead in the long term to a better prognosis. Further investigation is necessary to determine cardiovascular prognosis in ADPKD. The NEFRONA study is funded by a research grant from AbbVie and the Spanish government RETIC (RD12/0021) and FIS PS10/00946. Torra R research is funded by the Instituto de Salud Carlos III/Fondo Europeo de Desarrollo Regional (FEDER) funds, RETIC REDINREN RD16/0009 FIS FEDER FUNDS (PI15/01824, PI18/00362).

yearjournalcountryeditionlanguage
2021-03-25
10.1186/s12882-021-02313-1https://hdl.handle.net/10459.1/72365